Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Byoung Chul Cho, MD, PhD
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
Improving Adherence and Toxicity Monitoring in NSCLC Care
The Importance of Multidisciplinary Coordination in NSCLC Care
Laura Alder, MD
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026 Scottsdale, Arizona
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
A New Era of Hope in Non-Small Cell Lung Cancer Care
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Benjamin Garmezy, MD
Moving Toward Biomarker-Driven Care in Bladder Cancer
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.